Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.40 |
| ▸ | PKLR | P30613 | 11/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038904 | 0.95 | QPCT (0.49) | QPCTPKLRMAPT | |
| Trifluoroacetic Acid SCHEMBL1386305 | 0.75 | QPCT (0.45) | QPCTSLC2A1PKLRCACNA1BMAPT | |
| SCHEMBL4041098 | 0.75 | FABP1 (0.45) | PKLRMAPT | |
| Trifluoroacetic Acid SCHEMBL4034917 | 0.74 | QPCT (0.49) | QPCTSLC2A1CACNA1BMAPTUSP2 | |
| SCHEMBL4037678 | 0.74 | GAA (0.46) | PKLRMAPT | |
| SCHEMBL4032961 | 0.73 | PKM (0.49) | PKLRMAPTHTTSMN1; SMN2 | |
| SCHEMBL4037687 | 0.70 | GAA (0.45) | PKLRMAPT | |
| Trifluoroacetic Acid SCHEMBL4034617 | 0.67 | QPCT (0.44) | QPCTCACNA1BMAPTUSP2LMNA | |
| SCHEMBL4035617 | 0.64 | ALDH1A1 (0.46) | MAPTUSP2LMNAHTTSMN1; SMN2 | |
| SCHEMBL4038936 | 0.62 | LMNA (0.49) | PKLRLMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | claimed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | claimed |
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | QPCT 55/4885SLC2A1 3876/4885PKLR 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.